HIGHS AND LOWS IPOS OPTIONS SEC FILINGS
DAILY RATINGS & NEWS FOR AXSOME THERAPEUTICS
Complete the form below to receive the latest headlines and analysts' recommendations for Axsome Therapeutics with our free daily email newsletter:
RECENT POSTS
Alphabet Inc (NASDAQ:GOOGL) Shares Acquired by Bristol John W & Co. Inc. NY
Bristol John W & Co. Inc. NY Boosts Holdings in Amazon.com, Inc. (NASDAQ:AMZN)
Bristol John W & Co. Inc. NY Boosts Stake in JPMorgan Chase & Co. (NYSE:JPM)
Bristol John W & Co. Inc. NY Has $94.89 Million Stock Position in Apple Inc. (NASDAQ:AAPL)
Bristol John W & Co. Inc. NY Grows Stock Position in Johnson & Johnson (NYSE:JNJ)
Ferguson Wellman Capital Management Inc. Has $83.59 Million Stock Holdings in Procter & Gamble Co (NYSE:PG)
Pflug Koory LLC Has $1.43 Million Position in Johnson & Johnson (NYSE:JNJ)
Ferguson Wellman Capital Management Inc. Purchases 21,292 Shares of Sumitomo Mitsui Financial Grp, Inc. (NYSE:SMFG)
Genesee Capital Advisors LLC Invests $1.74 Million in Walt Disney Co (NYSE:DIS)
Cisco Systems, Inc. (NASDAQ:CSCO) Shares Sold by Ferguson Wellman Capital Management Inc.
Ferguson Wellman Capital Management Inc. Grows Stake in Check Point Software Technologies Ltd. (NASDAQ:CHKP)
Ferguson Wellman Capital Management Inc. Decreases Stock Position in Kimberly Clark Corp (NYSE:KMB)
Ferguson Wellman Capital Management Inc. Increases Holdings in PepsiCo, Inc. (NASDAQ:PEP)
Ferguson Wellman Capital Management Inc. Has $36.32 Million Stock Holdings in Exxon Mobil Co. (NYSE:XOM)
Bristol-Myers Squibb Co (NYSE:BMY) Stock Holdings Lifted by Ferguson Wellman Capital Management Inc.
Chevron Co. (NYSE:CVX) Holdings Reduced by Ferguson Wellman Capital Management Inc.
GlaxoSmithKline plc (NYSE:GSK) Shares Acquired by Ferguson Wellman Capital Management Inc.
Alphabet Inc (NASDAQ:GOOGL) Stake Boosted by Ferguson Wellman Capital Management Inc.
Walt Disney Co (NYSE:DIS) Shares Bought by Ferguson Wellman Capital Management Inc.
Ferguson Wellman Capital Management Inc. Sells 42,840 Shares of SAP SE (NYSE:SAP)
Axsome Therapeutics (NASDAQ:AXSM) Now Covered by Analysts at Guggenheim
Posted by ABMN Staff on Oct 16th, 2019 // No Comments
Axsome Therapeutics logoResearch analysts at Guggenheim assumed coverage on shares of Axsome Therapeutics (NASDAQ:AXSM) in a report issued on Wednesday, Briefing.com Automated Import reports. The firm set a “buy” rating and a $48.00 price target on the stock. Guggenheim’s target price would suggest a potential upside of 132.67% from the company’s previous close.
AXSM has been the subject of a number of other reports. HC Wainwright set a $30.00 price target on shares of Axsome Therapeutics and gave the company a “buy” rating in a report on Monday, June 24th. BidaskClub lowered shares of Axsome Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. ValuEngine lowered shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Zacks Investment Research raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 7th. Finally, William Blair began coverage on shares of Axsome Therapeutics in a report on Wednesday, September 18th. They set an “outperform” rating and a $48.00 price target for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. Axsome Therapeutics presently has a consensus rating of “Buy” and an average target price of $35.13.
Get Axsome Therapeutics alerts:
Shares of AXSM stock opened at $20.63 on Wednesday. The company’s fifty day simple moving average is $23.34 and its 200-day simple moving average is $22.42. Axsome Therapeutics has a 52 week low of $1.94 and a 52 week high of $30.50. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.72. The company has a market cap of $624.18 million, a PE ratio of -17.94 and a beta of 2.59.